{"_id": "6501388afddc0bb1312fb025", "Not yet fixed MQL": "{\n\"and\": [\n{\n\"$and\": [\n{\"prostate cancer histology\": \"adenocarcinoma\"},\n{\"prostate cancer histology\": {\"$not\": \"small cell\"}}\n]\n},\n{\"prostate cancer progression on androgen deprivation therapy\": {\"$lt\": 180}},\n{\"metastatic disease\": {\"$or\": [\n{\"bone lesions\": true},\n{\"soft tissue disease\": true}\n]}},\n{\"abiraterone acetate exposure\": {\"$in\": [\n\"abiraterone-na\u00efve\",\n\"received prior abiraterone acetate for the treatment of mHSPC or mCRPC, for a minimum of 4 weeks and not progressed while on treatment\",\n\"received prior abiraterone acetate for the treatment of mHSPC or mCRPC and progressed on treatment after a minimum of 8 weeks treatment (minimum 14 weeks for those with bone progression)\"\n]}},\n{\"androgen deprivation\": {\"$lt\": 50}},\n{\"bone resorptive therapy\": true},\n{\n\"$and\": [\n{\"refrain from donating sperm\": true},\n{\"$or\": [\n{\"be abstinent\": true},\n{\"must agree to use male condom\": true}\n]}\n]\n},\n{\"biopsy sample\": {\"$or\": [\n{\"soft tissue biopsy\": true},\n{\"bone biopsy\": true}\n]}},\n{\"ECOG performance status\": {\"$in\": [0, 1]}}\n]\n},\n{\n\"$not\": {\n\"$or\": [\n{\"additional malignancy\": true},\n{\"autoimmune disease\": true},\n{\"immunodeficiency\": true},\n{\"major surgery\": true},\n{\"gastrointestinal disorder\": true},\n{\"active infection\": true},\n{\"pneumonitis/interstitial lung disease\": true},\n{\"HIV infection\": true},\n{\"CNS metastases\": true},\n{\"hypersensitivity\": true},\n{\"seizure history\": true},\n{\"loss of consciousness history\": true},\n{\"hypotension\": true},\n{\"bradycardia\": true},\n{\"ketoconazole treatment\": true},\n{\"prior anti-PD-1/PD-L1/PD-L2 therapy\": true},\n{\"prior radium or radiopharmaceutical treatment\": true},\n{\"prior docetaxel or chemotherapy treatment\": true},\n{\"prior anti-cancer monoclonal antibody therapy\": true},\n{\"herbal product use\": true},\n{\"live vaccine use\": true},\n{\"participation in investigational study\": true},\n{\"'superscan' bone scan\": true},\n{\"expecting to conceive or father children\": true},\n{\"allogenic tissue/solid organ transplant\": true}\n]\n}\n}\n]\n}", "nctId": "NCT03834493", "title": "A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)"}